Norwood Investment Partners LP Buys New Position in Cellebrite DI Ltd. $CLBT

Key Points

• Norwood Investment Partners bought a new position of 230,671 shares in Cellebrite DI during Q3 (about $4.27M), representing roughly 3.7% of Norwood’s portfolio and making CLBT its 10th largest holding.
• Cellebrite reported Q4 EPS of $0.14 (in line with consensus) and revenue of $128.82M (above expectations), with revenue up 28.8% year-over-year and a 16.47% net margin.
• The stock trades around $14.16 (up 3.1%), has a market cap of $3.39B, and carries a consensus analyst rating of “Moderate Buy” with an average target price of $22.50.

Norwood Investment Partners LP purchased a new position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 230,671 shares of the company's stock, valued at approximately $4,274,000. Cellebrite DI makes up approximately 3.7% of Norwood Investment Partners LP's portfolio, making the stock its 10th largest position. Norwood Investment Partners LP owned approximately 0.10% of Cellebrite DI at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Y.D. More Investments Ltd lifted its position in shares of Cellebrite DI by 76.2% during the second quarter. Y.D. More Investments Ltd now owns 441,579 shares of the company's stock worth $7,065,000 after purchasing an additional 191,020 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in Cellebrite DI by 40.4% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 359,764 shares of the company's stock worth $6,652,000 after buying an additional 103,568 shares during the period. Y Intercept Hong Kong Ltd purchased a new stake in Cellebrite DI during the 2nd quarter worth $657,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Cellebrite DI in the 3rd quarter worth $19,457,000. Finally, Moody National Bank Trust Division purchased a new position in Cellebrite DI in the 3rd quarter valued at about $2,670,000. Institutional investors and hedge funds own 45.88% of the company's stock.

Cellebrite DI Trading Up 3.1%

Shares of CLBT opened at $14.16 on Thursday. Cellebrite DI Ltd. has a 52 week low of $11.76 and a 52 week high of $20.86. The firm has a market cap of $3.39 billion, a price-to-earnings ratio of 45.68, a PEG ratio of 2.11 and a beta of 1.30. The stock has a 50 day moving average of $15.74 and a 200-day moving average of $16.96.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings data on Wednesday, February 11th. The company reported $0.14 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.14. The firm had revenue of $128.82 million for the quarter, compared to analysts' expectations of $126.07 million. Cellebrite DI had a return on equity of 20.43% and a net margin of 16.47%.The firm's revenue for the quarter was up 28.8% on a year-over-year basis. During the same period last year, the business posted $0.10 earnings per share. On average, sell-side analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Analyst Ratings Changes

CLBT has been the topic of a number of analyst reports. Bank of America lifted their target price on Cellebrite DI from $24.00 to $25.00 and gave the stock a "buy" rating in a research report on Thursday, November 13th. JPMorgan Chase & Co. lifted their price objective on Cellebrite DI from $23.00 to $24.00 and gave the stock an "overweight" rating in a report on Thursday, November 13th. Wall Street Zen cut Cellebrite DI from a "buy" rating to a "hold" rating in a research note on Saturday, November 8th. Lake Street Capital lifted their price target on shares of Cellebrite DI from $22.00 to $23.00 and gave the stock a "buy" rating in a research note on Thursday, November 13th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Cellebrite DI in a report on Monday, December 29th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $22.50.

Cellebrite DI Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company's technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company's flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.